Nomenclature of monocytes and dendritic cells in blood.

By L. Ziegler-Heitbrock, P. Ancuța, S. Crowe, M. Dalod, V. Grau, D. Hart, P. Leenen, Yong‐jun Liu, G. Macpherson, G. Randolph and 8 more. Blood, 2010

2,444 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/03341c81be9de5a1210b252ac2b2b6b2c11cc177

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. P. Italiani
2. D. Boraschi
3. S. Yona
4. C. Shi
5. L. Cañedo-Dorantes
6. Mara Cañedo-Ayala
7. G. Harry
8. Eric G. Pamer

Citations in the corpus

• Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases (2014, background): “MC, monocyte; AMI, acute myocard human leukocyte antigen DR (MHC-II, major histocompatibility complex class II); TNFα, subsets in 2010, and classified human monocytes subsets as classical monocytes (CD14CD16), intermediate monocytes (CD14CD16), and non-classical monocytes (CD14CD16) [32].”
• The three human monocyte subsets: implications for health and disease (2012, background): “A new nomenclature defines human monocyte subsets into three, where the minor CD16? population is further segregated into two smaller subpopulations [14].”
• From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation (2014, methodology): “%) is further subdivided into the intermediate subset, with low CD16 and high CD14 (CD14++CD16+ or CD14+CD16+), and the non-classical subset, with high CD16 but with relatively lower CD14 expression (CD14+CD16++ or CD14dimCD16+) (31).”
• Microglial M1/M2 polarization and metabolic states (2016, background): “Alternatively, subpopulations of macrophages within an injury environment may express specific phenotypes resulting in concurrent expression of M1and M2-related factors or mixed M1/M2 phenotypes (Ziegler-Heitbrock et al., 2010; Pettersen et al., 2011; Wong et al., 2011; Vogel et al., 2013).”
• International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors (2014, neutral): “Human DCs are subdivided into CD104 plasmacytoid DCs and conventional (or myeloid) CD11c DCs, the latter consisting of a CD16 subset (;70%), a CD1c (also called BDCA-1 from blood dendritic cell antigen-1) subset (;30%), and a CD141 (thrombomodulin, also called BDCA-3) subset (,5%) (Ziegler-Heitbrock”
• Skin Acute Wound Healing: A Comprehensive Review (2019, methodology): “In the blood, three monocyte subsets with different phenotypes have been identified [55]: CD14CD16 classical monocytes (inflammatory) capable of transmigrating and entering tissues, CD14CD16 intermediate monocytes with increased proangiogenic and antigen processing and presentation activities, and C”
• The fate and lifespan of human monocyte subsets in steady state and systemic inflammation (2017, background): “ 1 a; Ziegler-Heitbrock et al., 2010).”
• Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. (2011, methodology): “It has been proposed that the intermediate subset is a transitional population bridging between the classical and nonclassical monocyte subsets.(16,17) In M-CSF treated patients, intermediate monocytes were expanded prior to the nonclassical subset.”
• Monocyte recruitment during infection and inflammation (2011, background): “CD14 ++ CD16 − monocytes, which are also referred to as classical monocyte”